It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

The panel voted 21 to zero that Beyfortus (nirsevimab) appears to be safe and effective at preventing RSV infections in newborns and infants as they face their first RSV season, setting the drug ...

Upcoming market catalysts for the second quarter of 2025 include the US approval decisions for clesrovimab (MK-1654) for respiratory syncytial virus (RSV) prophylaxis, sebetralstat for hereditary ...

A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

After hours: March 13 at 7:52:11 PM EDT Loading Chart for AZN ...

At close: 5:29:54 PM GMT+1 Loading Chart for AZN.ST ...